Orchestra BioMed Hldgs Q4 EPS $(0.37) Beats $(0.38) Estimate, Sales $262.00K Miss $990.00K Estimate
Orchestra BioMed Hldgs Q4 EPS $(0.37) Beats $(0.38) Estimate, Sales $262.00K Miss $990.00K Estimate
Orchestra BioMed Hldgs第四季度每股收益美元（0.37）超过预期（0.38），销售额为26.2万美元，低于预期的990.00万美元
Orchestra BioMed Hldgs (NASDAQ:OBIO) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.38) by 2.63 percent. This is a 428.57 percent decrease over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $262.00 thousand which missed the analyst consensus estimate of $990.00 thousand by 73.54 percent.
Orchestra BioMed Hldgs（纳斯达克股票代码：OBIO）公布的季度亏损为每股0.37美元，比分析师共识估计的美元（0.38美元）高出2.63个百分点。这比去年同期每股亏损0.07美元（0.07）下降了428.57％。该公司公布的季度销售额为26.2万美元，比分析师普遍预期的990,000美元低73.54％。
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。